Building the Next Generation
of Precision Oncology Therapeutics
A selective precision oncology platform targeting critical drivers of tumor proliferation, survival, and resistance.
Alaw Therapeutics is a biotechnology company developing precision oncology therapeutics designed to address critical oncogenic dependencies and mechanisms of therapeutic resistance through highly selective small-molecule inhibitors. Our programs are engineered to address aggressive and resistant tumor biology where existing therapies may be limited by off-target toxicity, inadequate CNS exposure, or incomplete coverage of clinically relevant mutations.
Founded in 2024, Alaw Therapeutics is advancing a pipeline of differentiated precision oncology programs, including AL-605, a uniquely selective, brain-penetrant CDK2 inhibitor; AL-433, a uniquely selective, brain-penetrant CDK4 inhibitor; and AL-273, a next-generation pan-mutant EGFR inhibitor designed to address a broad spectrum of clinically relevant EGFR mutations and resistance mechanisms.
Investors
Selective. Programmable. AI-Driven.
-
We develop highly selective precision therapeutics designed to control oncogenic signaling while minimizing off-target activity and expanding the therapeutic window across resistant and aggressive cancers.
-
Our platform integrates selective small molecules and next-generation targeted degradation approaches to enable programmable control of tumor proliferation, survival, and adaptive signaling pathways.
-
Alaw integrates proprietary data, 3D/4D hybrid machine-learning models, docking, virtual screening, scaffold hopping, and ADMET modeling to accelerate rational drug design.
